What is Izon Science?
Izon Science Limited operates at the intersection of advanced diagnostics and nanoparticle research. The company is recognized for its proprietary qEV platform, which utilizes size exclusion chromatography to isolate and measure extracellular vesicles and nanoparticles with high precision. By providing researchers and clinical organizations with the tools required for reproducible particle characterization, Izon Science has established itself as a critical infrastructure provider in the development of therapeutics and diagnostic assays. Their commitment to scaling purification processes from laboratory-scale research to clinical-grade applications positions them as a vital partner in the evolving landscape of precision medicine and molecular diagnostics.
How much funding has Izon Science raised?
Izon Science has raised a total of $137K across 1 funding round:
Debt
$137K
Debt (2021): $137K with participation from PPP
Key Investors in Izon Science
PPP
Public-Private Partnership
What's next for Izon Science?
Following this late-stage financing, Izon Science is well-positioned to expand its global footprint and enhance its R&D capabilities. The strategic allocation of this capital will likely focus on scaling the production of its advanced instrumentation and broadening its reach within the therapeutic development market. As the demand for standardized extracellular vesicle analysis grows, Izon Science is expected to leverage its technical expertise to capture additional market share, potentially through the development of next-generation diagnostic tools and the strengthening of its commercial partnerships. The company remains focused on maintaining its reputation for high-quality, reproducible results while navigating the complexities of clinical-stage integration.
See full Izon Science company page
